<- Go Home
NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Market Cap
$10.9M
Volume
134.1K
Cash and Equivalents
$27.7M
EBITDA
-$54.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.27
52 Week Low
$0.35
Dividend
N/A
Price / Book Value
0.17
Price / Earnings
-0.20
Price / Tangible Book Value
0.17
Enterprise Value
-$51.7M
Enterprise Value / EBITDA
0.97
Operating Income
-$57.2M
Return on Equity
61.87%
Return on Assets
-34.23
Cash and Short Term Investments
$68.6M
Debt
$5.9M
Equity
$65.5M
Revenue
N/A
Unlevered FCF
-$23.2M
Sector
Biotechnology
Category
N/A